 |
Dan Kaplan, M.D., Ph.D.
Assistant Professor
Department of Dermatology
Washington University, 1998, M.D., Ph.D.
dankaplan@umn.edu
Kaplan Lab
Website
612-626-9400 office
612-624-5664 lab
|
Research Interests:
Langerhans & Dendritic Cells of the Skin
Unlike antigen introduced systemically, the development of
immune responses against antigen at barrier surfaces is relatively
poorly studied. It is clear, however, that tissue resident
dendritic cells (DC) play a central role. They are capable
of acquiring antigen and migrating to regional lymph node
(LN) where they activate T cells and thereby initiate adaptive
immune responses. Commensal organisms at barrier sites, however,
are tolerated by the immune system. Since antigens from these
organisms are not present in the thymus where central tolerance
is established, responses against commensal organisms are
limited through the development of peripheral tolerance. This
process is incompletely understood, but appears to rely on
specialized DC subpopulations that actively inhibit antigen-
specific T cell responses in the regional LN.
The lab’s focus is the early events after antigen exposure
in the skin that allows for the development of appropriate
immune responses to pathogens while limiting responses directed
against commensal organisms. We are concentrating on two opposing
dendritic cell (DC) subsets in the skin. We have previously
shown that DC in the epidermis (the outermost layer of skin),
termed Langerhans cells (LC) suppress the development of skin
immune responses while DC that reside deeper in the skin,
dermal DC, are required for the development of skin immune
responses. This is consistent with a model in which LC specialize
in limiting effector responses against commensal organisms.
According to this model, antigen found exclusively in the
epidermis is presented by LC leading to no response or tolerance
and thereby prevents deleterious immune responses against
commensal organisms. For invasive pathogens which penetrates
through the epidermis, antigen is present in both the epidermis
and dermis. In this situation antigen is acquired by both
dermal DC which are responsible for the generation of effector
responses, and by epidermal LC which inhibit that response.
We have engineered mice that have either constitutive or
inducible depletion of LC. We have also employed Cre-lox systems
to constitutively or inducibly ablate genes of interest selectively
in LC. By combining these unique strains of mice with models
of skin inflammation such as allergic contact dermatitis and
infection, we are able to examine the function of Langerhans
cells and the molecular mechanisms underlying these functions.
Selected Recent Publications:
- Igyarto, B, Jenison M., Dudda J., Roers A., Muller W.,
Koni P., Campbell D., Kaplan D.H., “Langerhans cells
suppress CHS responses via cognate CD4 interaction and LC-derived
IL-10” J. Exp. Med. Submitted
- Vesely D.L., Fish. D, Shlomchik M.J., Kaplan D.H., Bockenstedt
LK. 2009. “Langerhans Cell Deficiency Impairs Ixodes
scapularis Suppression of Th1 Responses in Mice”,
Infection
and Immunity, 77:5; 1881-1887.
- Obhrai, J.S., Oberbarnscheidt, M., Zhang N., Mueller D.L.,
Shlomchik, W.D., Lakkis, F.G., Shlomchik, M.J., Kaplan,
D.H. 2008. “Langerhans Cells Are Not Required For
Efficient Skin Graft Rejection” J.
Invest. Dermatology, 128:1950-1955.
- Strid, J., Roberts S.J., Filler, R.B., Lewis, J.M., Kwong,
B.Y., Schpero W., Kaplan, D.H., Hayday A.C., Girardi, M.
2008. “NKG2D-ligand upregulation promoted rapid reorganization
of a local immune compartment with pleiotropic effects on
carcinogenesis.” Nature
Immunology. 9:146-154.
- Bursch, L.S., Wang, L., Igyarto, B., Kissenpfennig, A.,
Maslissen B., Kaplan, D.H., Hoqguist K.A. 2007, “Identification
of a Novel Population of Langerhans Cells” J.
Exp. Med. 204:3147-56.
- McNiff, J.M., Kaplan, D.H. 2007 “Plasmacytoid Dendritic
Cells are Present in Cutaneous Dermatomyositis Lesions in
a Pattern Distinct from Lupus Erythematosus” J.
Cutan. Pathol.35(5):452-6
- Kaplan, D.H., Jenison, M.D., Li, M.O., Flavell, R.A.,
Shlomchik, M.J. 2007 “Autocrine TGFb is required for
Langerhans Cell Development.” J
Exp Med. 204:2545-52.
- Kaplan D.H., Jenison, M.C., Shlomchik W.D., Shlomchik
M.J. 2005 “Langerhans Cell Deficient Mice Develop
Enhanced Contact Hypersensitivitiy”. Immunity
23:611-620.
- Kaplan D.H., Anderson B.E., Shlomchik W.D., Shlomchik
M.J. 2004 “Tissues affected by graft-versus-host disease
vary with MHC haplotype in MHC-matched, MiHA-incompatable
murine models”.
J Immunol 173:5467-5475.
Last modified on: August 11, 2009 |